Protecting effect of N-acetylcysteine on myocard during CABG
Not Applicable
- Conditions
- Atherosclerotic cardiovascular disease.Atherosclerotic cardiovascular disease
- Registration Number
- IRCT201211062883N3
- Lead Sponsor
- Mazandaran Uiversity of Medical Sciences and Health Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
patients who candidate for CABG with EF below 50% at Mazandaran Heart Center
Exclusion critera:Valvular heart diseases; renal failure; liver disease; cross clamp time more than 1:30 min & use of intraaotric baloon pomp
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ejection fraction of LV. Timepoint: before operation & 5 day after operation. Method of measurement: echocardiograph.
- Secondary Outcome Measures
Name Time Method Arhythmia. Timepoint: during operation & ICU stay. Method of measurement: monitor.